Breast cancer stem cells (CSC) are believed to play a relevant role in tumor growth and relapse, metastization and active evasion to standard chemotherapy, thus representing an important tumor target. The objective of this work was to assess whether nucleolin was a receptor expressed in both breast cancer stem cells and non-stem cancer cells and whether it could be exploited to target nanoparticles-encapsulating drug combinations.
